Eugia – Recall of acyclovir injection

- On December 22, 2022, Eugia announced a consumer level recall of a single lot of acyclovir 1000 mg/20 mL due to product complaint of “dark particles” inside the vial.
    - Other acyclovir injection products that are not being recalled are available.
- This recalled lot was distributed nationwide May 2022.

Product Description	NDC#	Lot# (Expiration Date)
Acyclovir sodium injection 1000 mg per 20 mL (50 mg/mL)	55150-155-20	AC22004 (8/2023)

- Acyclovir injection is used for the treatment of herpes simplex infections in immunocompromised patients, initial episodes of herpes genitalis, herpes simplex encephalitis, neonatal herpes simplex virus infection, and varicella-zoster infections in immunocompromised patients.
- Patients who have the recalled acyclovir should contact their physician or health care provider if they have experienced any problems that may be related to using the recalled product.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.
- For any questions regarding this recall, call Qualanex at **1-800-505-9291**.